Supercharge Your Innovation With Domain-Expert AI Agents!

cd47 antagonists and uses thereof

A CDR1-CDR3, antigen technology, applied in the field of biomedicine or biopharmaceuticals, can solve problems such as insufficient anti-tumor effect

Active Publication Date: 2022-07-22
SHANDONG BIOANTY BIOLOGICAL TECH CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the CD47 antibodies currently in clinical use or on the market still have deficiencies in terms of antibody affinity, immunogenicity, side effects, and anti-tumor effects. Therefore, the development of candidate antibodies for this target with better effects is urgently needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • cd47 antagonists and uses thereof
  • cd47 antagonists and uses thereof
  • cd47 antagonists and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1. Generation of anti-CD47 monoclonal antibodies

[0064] 1.1 Immunization program

[0065] BoAn-hMab1 transgenic mice with Boan human antibody were immunized with CD47-His (ACROBiosystems, cat. no. CD7-H5227) or CD47-mFc (ACROBiosystems, cat. no. CD7-H52A5) emulsified with Freund's adjuvant. Freund's complete adjuvant was used for the first immunization, and Freund's incomplete adjuvant was used for the second to sixth immunization. A total of 20 mice were immunized this time, and serum titers were detected by Elisa. Coat the protein CD47-His (ACROBiosystems, catalog number CD7-H5227) with a concentration of 1ug / ml with CBS coating solution (pH9.6 carbonate solution), 100ul / well overnight at 4 degrees; block with 3% skimmed milk powder at 37 degrees for 1h ; Dilute the serum to 100X, 500X, 2500X, 12500X with PBST, add 100ul to each well. Incubate at 37°C for 1h; then add HRP-goat anti-human antibody (474-1006, KPL), incubate at 37°C for 1h, after color devel...

Embodiment 2

[0081] Example 2. Molecular construction and production of blocking antibodies

[0082] The clones CD47QMix-136\189, CD47Q6-155, CD47Q19-210 (hereinafter referred to as clone "136 / 189 / 155 / 210") were sent to Invitrogen Biotechnology Co., Ltd. for sequencing. The sequences are shown in Table 2.

[0083] Table 2. Amino acid sequences of candidate clones

[0084]

[0085]

[0086] Sequence analysis found that clone 155, clone 189 and clone 210 had N-glycosylation sites, and primers were designed to mutate them to obtain clones 155.1, 189.1 and 210.1, respectively. The heavy chain of clone 155.1 belongs to the germline gene IGHV4-34 family by sequence analysis, and the light chain belongs to the germline gene IGKV4-1 family. The amino acid sequence of each clone is as follows in Table 3:

[0087] Table 3. Amino acid sequences of candidate clones

[0088]

[0089] The antibody variable region gene was amplified by conventional molecular biology PCR (2*Phanta Max Master M...

Embodiment 3

[0099] Example 3. Characterization of Candidate Antibodies

[0100] 3.1 Forte Bio detects the affinity of candidate antibodies to CD47 protein

[0101] Antibody binding kinetics were measured using an OctetRED 96 instrument based on Biolayer Interferometry BLI. The antibody (10 μg / mL) was coupled to PROA Biosensors, the loading height was 1 nm, and the CD47 was serially diluted 2-fold with PBST, starting at 25 nM, and set to 0 concentration, the Association time was set to 300s, and the Dissociation time was set to 300s. After the detection, the binding constant (kon) and the dissociation constant (kdis) were calculated using Curve Fitting of 1:1 Model, and the equilibrium dissociation constant (kD) was calculated as the ratio kd / ka. The results are shown in Table 4. Compared with the control antibody, the affinity of the four candidate antibodies is higher than that of the control antibody except that the KD of CD47Q19-210.1-IgG4 is similar to that of the control antibody. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to antibodies or antigen-binding fragments thereof that bind to the CD47 antigen, and preparation methods, compositions and applications thereof. The antibody of the present invention has good interaction with CD47 antigen, can be used for preparing anti-CD47 antibody drug, and can be used for treating and / or preventing CD47-related diseases, such as cancer. It can also be used for immunological detection of CD47 antigen.

Description

technical field [0001] The present invention relates to the technical field of biomedicine or biopharmaceuticals, and more particularly to human anti-CD47 antibodies, their coding sequences, preparation methods, compositions and applications. Background technique [0002] CD47, also known as integrin associated protein (IAP), is a member of the immunoglobulin superfamily. CD47 is widely expressed on the surface of cells and can interact with Signal regulatory protein α (SIRPα), thrombospondin-1 (TSP1) and integrins to mediate apoptosis, proliferation, immunity, etc. A series of reactions (Maes T, Joos GF, Brussels GG. Am JRespir Cell Mol Biol. 2012;47(3):261-270). [0003] The human body needs 20-30trillion of red blood cells to keep oxygen efficiently transported throughout the body. The life cycle of red blood cells is only 120 days, and 10 billion red blood cells are produced every hour, and countless senescent red blood cells are phagocytosed and cleared by macrophages...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28A61K39/395A61P35/00A61P35/02A61P37/06A61P25/00A61P37/02
CPCC07K16/2803A61P35/00A61P35/02A61P37/06A61P25/00A61P37/02C07K2317/565C07K2317/92A61K2039/505
Inventor 宋德勇徐洪光韩静韩镇窦昌林曹发扬
Owner SHANDONG BIOANTY BIOLOGICAL TECH CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com